VELMENI Secures FDA Nod for Advanced AI-Driven 3D Dental Imaging

Date:

Share post:

Sunnyvale, California-based dental AI firm VELMENI announced on July 23, 2026, that the U.S. FDA has granted 510(k) clearance for its latest software, VELMENI for DENTISTS (V4D) 3D. The approval extends the company’s existing 2D imaging technology into three-dimensional cone-beam CT (CBCT) analysis, giving dental professionals a broader AI-driven toolkit for scan interpretation.

The new system helps clinicians segment anatomical structures, generate panoramic and cross-sectional reconstructions, take precise measurements, and produce exportable 3D models — features aimed at supporting implant planning, orthodontics, surgery, and airway evaluation. It’s built for general dentists, specialists, dental service organizations, and imaging centersalike.

Company leadership described the release as part of a broader push toward unifying dental workflows rather than offering isolated imaging tools. Independent experts consulted by the company noted the software could improve efficiency without replacing clinical judgment, which remains with the treating practitioner.

The tool is now part of VELMENI ONE, the company’s integrated dental AI platform spanning imaging, documentation, and administrative automation.

Written By: Sayan Das

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Seven Clinical Trial Ethics Panels Lose CDSCO Registration in Compliance Crackdown

The Central Drugs Standard Control Organisation (CDSCO) has withdrawn registration certificates from seven Ethics Committees nationwide after risk-based...

From Research to Revolution: Novo Nordisk Shares Oral GLP-1 Breakthrough Story

Novo Nordisk has shared the scientific journey behind turning an injectable biologic medicine into a pill — a...

Biozenta Lifescience to Build ₹1,250 Crore Oncology Plant in Barabanki, UP

Biozenta Lifescience Pvt. Ltd., a global leader in oncology medicines, has announced plans to establish a state-of-the-art manufacturing facility in Barabanki, Uttar...

​Zydus Collaborates with ICMR to Address Sickle Cell Disease as Desidustat Enters Phase III

Zydus Lifesciences Limited, in collaboration with the Indian Council of Medical Research (ICMR), has announced the successful completion of...